Released June 01, 2020 | SUGAR LAND
en
Despite its status as an essential industry, the Pharmaceuticals & Biotech Industry has not escaped the effects of the COVID-19 pandemic. Across the globe, 565 reported projects representing more than $12 billion have been delayed or put on indefinite hold. Stay-at-home orders appear to be the number one cause, as companies scrambled to comply and secure the safety of essential workers inside of operational plants.
Most of the projects are expected to be revived as better understanding and guidelines for COVID-19 are developed. Click here for a list of projects and click on the graph below showing projects by sector.
The outlook for the Pharmaceuticals & Biotech Industry and others will be the topic of Industrial Info's complementary webinar sessions held June 3 and 4 at 10 a.m. and 1 p.m. each day.
Make sure to RSVP today!
Most of the projects are expected to be revived as better understanding and guidelines for COVID-19 are developed. Click here for a list of projects and click on the graph below showing projects by sector.
The outlook for the Pharmaceuticals & Biotech Industry and others will be the topic of Industrial Info's complementary webinar sessions held June 3 and 4 at 10 a.m. and 1 p.m. each day.
Make sure to RSVP today!
